FRS2 and neoplasm: To examine whether lenvatinib inhibited FGF signaling pathways within the Hep3B2.1‐7 and SNU‐398 xenograft tumors, tumor samples were collected 2 h after a single lenvatinib treatment, and phosphorylation levels of FRS2 and another downstream molecule of FGFR, Erk1/2, were evaluated.